Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2016

01-05-2016 | Research Letter

Insomnia does not mediate or modify the association between MTNR1B risk variant rs10830963 and glucose levels

Authors: Hanna M Ollila, Erkki Kronholm, Johannes Kettunen, Kaisa Silander, Markus Perola, Tarja Porkka-Heiskanen, Veikko Salomaa, Tiina Paunio

Published in: Diabetologia | Issue 5/2016

Login to get access

Excerpt

To the Editor: Short sleep and insomnia associate strongly with blood glucose levels and type-2 diabetes [1] and one of the possible mechanisms is that the same genetic variants regulate sleep and glucose metabolism. The single nucleotide polymorphism (SNP) rs10830963 in MTNR1B has been associated with type 2 diabetes and blood glucose levels [2]. Traditionally, melatonin is thought to be a ‘dark hormone’ as its expression is controlled by light from the retina to the pineal gland. In the elderly, melatonin can be used to treat insomnia and improve sleep quality [3]. …
Literature
1.
Cappuccio FP, D'Elia L, Strazzullo P, Miller MA (2010) Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 33:414–420CrossRefPubMedPubMedCentral
2.
3.
Wade AG, Ford I, Crawford G et al (2007) Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 23:2597–2605CrossRefPubMed
4.
5.
Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575CrossRefPubMedPubMedCentral
6.
Olsson L, Pettersen E, Ahlbom A, Carlsson S, Midthjell K, Grill V (2011) No effect by the common gene variant rs10830963 of the melatonin receptor 1B on the association between sleep disturbances and type 2 diabetes: results from the Nord-Trondelag Health Study. Diabetologia 54:1375–1378CrossRefPubMed
7.
Tare A, Lane JM, Cade BE et al (2014) Sleep duration does not mediate or modify association of common genetic variants with type 2 diabetes. Diabetologia 57:339–346CrossRefPubMedPubMedCentral
8.
Byrne EM, Johnson J, McRae AF et al (2012) A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor. Sleep 35:967–975PubMedPubMedCentral
9.
Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116CrossRefPubMedPubMedCentral
Metadata
Title
Insomnia does not mediate or modify the association between MTNR1B risk variant rs10830963 and glucose levels
Authors
Hanna M Ollila
Erkki Kronholm
Johannes Kettunen
Kaisa Silander
Markus Perola
Tarja Porkka-Heiskanen
Veikko Salomaa
Tiina Paunio
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3893-8

Other articles of this Issue 5/2016

Diabetologia 5/2016 Go to the issue

Short Communication

The anterior chamber of the eye is a transplantation site that supports and enables visualisation of beta cell development in mice

Commentary

Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care

Article

Genetic models rule out a major role of beta cell glycogen in the control of glucose homeostasis

Article

Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals

Short Communication

The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1

Review

Adipose tissue macrophages: going off track during obesity

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits